Neurocrine Biosciences to Participate at Investor Conferences in November

Company Participation in Conferences - Neurocrine Biosciences, Inc. will participate in three upcoming investor conferences in November 2024 [1] - The CEO, CFO, and VP of Investor Relations will present at the 2024 UBS Global Healthcare Conference on November 12, 2024 [2] - The CFO and Chief Commercial Officer will present at the Stifel 2024 Healthcare Conference on November 18, 2024 [2] - The CEO, CFO, and Chief Medical Officer will present at the Jefferies London Healthcare Conference on November 19, 2024 [3] Webcast Information - The live presentations will be webcast and accessible on Neurocrine Biosciences' website under the Investors section [4] - A replay of the webcasts will be available approximately one hour after the events and archived for about one month [4] Company Overview - Neurocrine Biosciences is a leading neuroscience-focused biopharmaceutical company dedicated to developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders [5] - The company has FDA-approved treatments for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, endometriosis, and uterine fibroids, along with a robust pipeline in mid- to late-phase clinical development [5] - Neurocrine has been applying insights into neuroscience for three decades to address complex conditions and aims to ease the burden of debilitating diseases [5]